Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 20, 2008. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 3,230,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,158.87 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.04% of total voting rights).
- Shares in Issue: 5,355,056,177 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 3,230,000 shares purchased on May 20, 2008. This transaction increased the proportion of shares held in Treasury to 9.04% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (3,230,000 shares at 1,158.87 pence) against cash flow statements in the most recent 20-F filing.
- Confirm the updated share count of 5,355,056,177 for calculating earnings per share (EPS) and voting thresholds.
- Note that the 9.04% Treasury holding represents shares that do not carry voting rights.